Age-Related Macular Degeneration Bibliography

  DownloadsFellow Members Only

AMD Review/Classification

Ferris FL III, Wilkinson CP, Bird A, et al; Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration [published online January 16, 2013]. Ophthalmology. 2013;120(4):844-851. doi:10.1016/j.ophtha.2012.10.036.

Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738. doi:10.1016/S0140-6736(12)60282-7.

AMD Epidemiology

Chakravarthy U, Wong TY, Fletcher A, et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.  BMC Ophthalmol. 2010;10:31. doi:10.1186/1471-2415-10-31.

Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE.  Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253–262. doi:10.1016/j.ophtha.2006.10.040.

AMD Genetics

Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together [published online April 16, 2014]. Annu Rev Genomics Hum Genet. 2014;15:151-171. doi:10.1146/annurev-genom-090413-025610.

Klein RJ, Zeiss C, Chew EY, et al.  Complement factor H polymorphism in age-related macular degeneration [published online March 10, 2005]. Science. 2005;308(5720):385–389. doi:10.1126/science.1109557.

AMD and Depression

Casten RJ, Rovner BW. Update on depression and age-related macular degeneration. Curr Opin Ophthalmol. 2013;24(3):239-243. doi:10.1097/ICU.0b013e32835f8e55.

AREDS /AREDS2 Trial

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. doi:10.1001/archopht.119.10.1417.

Aronow ME, Chew EY. Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions. Curr Opin Ophthalmol. 2014;25(3):186-190. doi:10.1097/ICU.0000000000000046.

Chew EY, Clemons TE, SanGiovanni JP, et al; Age-Related Eye Disease Study 2 (AREDS2) Research Group. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report no. 3. JAMA Ophthalmol. 2014;132(2):142-149. doi:10.1001/jamaophthalmol.2013.7376.

Macular Photocoagulation Study

Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol.1991;109(8):1109-1114. doi:10.1001/archopht.1991.01080080069030.

Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1982;100(6):912–918. doi:10.1001/archopht.1982.01030030920003.

Photodynamic Therapy/ Visudyne

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol. 2001;119(2):198–207. doi:10-1001/pubs.Ophthalmol.-ISSN-0003-9950-119-2-ecs00156.

Ranibizumab

Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481.

Ranibizumab vs Bevicizumab (CATT Trial) and Safety

CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration [published online April 28, 2011]. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673.

Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;(9):1-87. doi:10.1002/14651858.CD011230.pub2.

Aflibercept

Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published online October 17, 2012]. Ophthalmology. 2012;119(12):2537-2548. doi:10.1016/j.ophtha.2012.09.006.

Stem Cells

Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies [published online October 15, 2014]. Lancet. 2014;385(9967):509-516. doi:10.1016/S0140-6736(14)61376-3.